MLAB Technical Analysis & Stock Price Forecast
Mesa Laboratories Inc. (MLAB) currently shows a "Strong Buy" technical sentiment based on an aggregation of 15 technical signals, with 11 indicators flashing buy and 4 indicating sell. The stock is trading above its 60-day and 200-day moving averages, suggesting a potentially bullish long-term trend, though its Relative Strength Index (RSI) is in neutral territory. Key resistance is at $94.029 and strong support is at $78.499.
MLAB Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an in-depth financial analysis of Mesa Laboratories Inc (MLAB), detailing its revenue breakdown, profitability margins, and a comparison with competitors. MLAB's primary revenue source is Discrete Revenues- Consumables, contributing 55.0% of total sales, and it maintains strong gross and operating margins. The article benchmarks MLAB's financial performance against industry rivals VREX and ANGO, highlighting its competitive standing within the Medical Equipment, Supplies & Distribution sector.
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026
Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. This dividend will be payable on June 15, 2026, to shareholders who are of record at the close of business on May 29, 2026. The announcement was made on April 3, 2026.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend will be paid on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa Labs is a global leader in life science tools and quality control solutions for regulated industries.
Mesa Labs Declares Quarterly Dividend
Mesa Laboratories, Inc. has announced a regular quarterly dividend of $0.16 per share of common stock, payable on June 15, 2026, to shareholders of record by May 29, 2026. This dividend demonstrates Mesa's financial stability and commitment to returning value to shareholders, despite industry and economic challenges. The consistent payout reflects the company's strong cash flow and positive long-term outlook in the life sciences and medical technology sectors.
Mesa Labs Declares Quarterly Dividend
Mesa Laboratories, Inc. has declared a regular quarterly dividend of $0.16 per share, payable on June 15, 2026, to shareholders of record by May 29, 2026. This dividend highlights the company's financial stability and its ongoing commitment to providing value to its shareholders. The consistent payout reinforces Mesa Labs' strong business model and its ability to generate stable cash flows.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is scheduled to be paid on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa Labs specializes in life science tools and quality control solutions for various regulated industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is set to be paid on June 15, 2026, to shareholders of record as of May 29, 2026. The company is a global leader in life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa Labs specializes in life science tools and quality control solutions for regulated industries.
Mesa Laboratories Inc. (MLAB) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Mesa Laboratories Inc. (MLAB), showing its current price, intraday change, and percentage change. It also includes information on average price target (currently N/A due to zero analyst ratings in the last 3 months) and notes the absence of earnings information. The content is presented by StocksToTrade.com, emphasizing that it is for informational purposes only and not investment advice.
Mesa Laboratories (MLAB) CEO RSUs expire as 8,211 units forfeited
Mesa Laboratories President and CEO Gary M. Owens reported the expiration and forfeiture of 8,211 restricted stock units (RSUs). These RSUs, initially scheduled to vest on June 15, 2028, were deemed expired on March 31, 2026, and returned to the company. Following this transaction, Owens still holds 16,448 restricted stock units directly.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ: MLAB) announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa is a global leader in life science tools and quality control solutions for regulated industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on June 15, 2026, to shareholders of record as of May 29, 2026. The company is a global leader in life science tools and quality control solutions for regulated industries.
Mesa Laboratories (NASDAQ:MLAB) Stock Price Passes Above 200-Day Moving Average - What's Next?
Mesa Laboratories (NASDAQ:MLAB) shares have moved above their 200-day moving average, signaling short-term bullish momentum, despite analysts maintaining a "Reduce" consensus rating with a $94 price target. The company recently exceeded earnings expectations and saw significant insider buying, while institutional investors also increased their holdings. However, MLAB's valuation shows a high P/E ratio of 138.22 and a modest dividend yield of 0.7%.
Vanguard disaggregates holdings after realignment — Mesa Laboratories (MLAB)
Vanguard has filed an amended Schedule 13G/A, reporting 0 shares beneficially owned in Mesa Laboratories (MLAB) following an internal realignment effective January 12, 2026. This amendment states that certain Vanguard subsidiaries or divisions will now report their beneficial ownership separately. The filing clarifies that while the reporting structure has changed, the underlying investment strategies of these subsidiaries remain the same.
Mesa Laboratories announces CEO transition and board resignation
Mesa Laboratories, Inc. announced the departure of President and CEO Gary Owens, effective April 13, 2026, with Dr. Siddhartha Kadia appointed as his successor. Owens will remain in a non-executive capacity for a transition period and his resignation from the board of directors is not due to any disagreement. The company has maintained dividend payments for 24 years and remains profitable, despite a 34% drop in stock price over the last year.
Mesa Laboratories announces CEO transition and board resignation
Mesa Laboratories, Inc. announced the planned departure of President and CEO Gary Owens, effective around April 13, 2026. Mr. Owens will receive severance and benefits and has resigned from the board. Dr. Siddhartha Kadia has been appointed as the new President and CEO, effective April 13, 2026, and will also join the Board of Directors.
Mesa Laboratories (NASDAQ: MLAB) sets CEO Owens transition and board exit
Mesa Laboratories has detailed the transition plan for President and CEO Gary Owens, whose departure is scheduled for April 13, 2026. Owens will remain in a non-executive role until June 22, 2026, to ensure a smooth handover and will receive severance benefits aligned with a "without cause" termination, including a pro-rated performance stock unit award, contingent on signing a release of claims. He also resigned from the board on March 20, 2026, a move the company states was not due to any disagreements.
Mesa Laboratories, Inc. $MLAB Shares Bought by Crawford Investment Counsel Inc.
Crawford Investment Counsel Inc. significantly increased its stake in Mesa Laboratories (NASDAQ:MLAB) by 59.4% during the third quarter, now owning 82,467 shares valued at $5.53 million. Several other institutional investors also bought shares, with 90.60% of the stock owned by institutions and hedge funds. The article also details recent analyst ratings, financial performance, and insider buying activity, including purchases by directors R Tony Tripeny and Shiraz Shabanali Ladiwala.
Simcoe Capital Management LLC Makes New Investment in Mesa Laboratories, Inc. $MLAB
Simcoe Capital Management LLC has made a new investment in Mesa Laboratories, Inc. (NASDAQ:MLAB), purchasing over 190,000 shares valued at approximately $12.79 million, making it their 14th-largest holding. This investment comes as Mesa Laboratories recently surpassed quarterly earnings expectations. Insider activity also shows directors increasing their stakes in the company, despite a high valuation and a 100% dividend payout ratio.
Long Path (MLAB) reports 311,703 shares, 5.6% ownership stake
Long Path Smaller Companies Fund, LP, along with affiliated entities and co-portfolio managers, has reported a beneficial ownership of 311,703 shares in Mesa Laboratories, Inc. (MLAB), constituting a 5.6% stake. This disclosure was made in a Schedule 13G filing with the SEC, indicating a passive investment. The percentage is based on 5,524,813 outstanding shares as of January 31, 2026.
Gabelli Funds LLC Grows Stake in Mesa Laboratories, Inc. $MLAB
Gabelli Funds LLC significantly increased its stake in Mesa Laboratories, Inc. (MLAB) by 114.6%, bringing their total holdings to 53,974 shares. Despite the company beating quarterly estimates with EPS of $3.07 and revenues of $65.13 million, the stock has recently decreased by 16.5%. Insiders have also been acquiring shares, and the company declared a $0.16 quarterly dividend.
[Form 4] MESA LABORATORIES INC /CO/ Insider Trading Activity
Mesa Laboratories director Shiraz Shabanali Ladiwala reported an open-market purchase of 3,500 shares of Mesa Laboratories common stock at $72.23 per share on March 10, 2026. This transaction increased his direct holdings to 8,523 shares, indicating a larger personal investment in the company. The SEC Form 4 filing details this acquisition, categorized as a positive insider trading event.
Mark Christopher Capone Acquires 1,301 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock
Mesa Laboratories (NASDAQ:MLAB) Director Mark Christopher Capone recently acquired 1,301 shares of the company's stock for a total of $99,331.35, increasing his stake by over 61%. This insider buying occurred as the stock experienced a 16.5% drop despite the company reporting better-than-expected quarterly earnings. The article also highlights analyst ratings, institutional investments, and the company's dividend payout.
Capone Mark Christopher buys Mesa Laboratories shares for $99,331
Director Capone Mark Christopher purchased 1,301 shares of Mesa Laboratories (NASDAQ:MLAB) for $99,331 on March 10, 2026, as per an SEC filing. This insider buying occurred after the stock experienced a nearly 20% drop, with shares trading at $73.47. The company recently announced a leadership change, with Dr. Siddhartha Kadia replacing Gary Owens as President and CEO.
Insider Buying: Mark Capone Acquires Shares of Mesa Laboratories Inc (MLAB)
Mark Capone, a Director at Mesa Laboratories Inc (MLAB), recently purchased 1,301 shares, increasing his total ownership to 3,429 shares. The acquisition occurred when shares were trading at $76.35, valuing the company at a market cap of $404.580 million. According to GuruFocus's GF Value, the stock is considered a "Possible Value Trap, Think Twice," with a price-to-GF-Value ratio of 0.64.
Insider Buying: Mesa Laboratories (NASDAQ:MLAB) Director Buys 3,500 Shares of Stock
Mesa Laboratories (NASDAQ:MLAB) Director Shiraz Shabanali Ladiwala recently purchased 3,500 shares of the company's stock for approximately $252,805, increasing his total holdings by nearly 70%. This insider buying occurred as MLAB shares experienced a notable decline, despite the company reporting better-than-expected earnings and maintaining a quarterly dividend. Analyst ratings for Mesa Laboratories are mixed, with a consensus of "Reduce" and a target price of $94.00.
Mesa Laboratories names new CEO
This article announces that Mesa Laboratories has appointed a new CEO. No further details about the new CEO or the company's future direction are provided in the current content.
Mesa Laboratories Names New CEO for Next Phase
Mesa Laboratories announced that CEO Gary Owens will step down on April 12, 2026, after leading the company since 2017. Dr. Siddhartha Kadia has been appointed as the new President, CEO, and director, effective April 13, 2026, with a compensation package designed to drive the company's next phase of growth. Spark’s AI Analyst rates MLAB stock as Neutral, citing strong cash generation but unstable net earnings and mixed technical momentum.
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Mesa Laboratories, Inc. announced that Gary Owens will step down as President and CEO on April 12, 2026, after leading significant growth and expansion for the company since 2017. Dr. Siddhartha Kadia has been appointed as the new President and CEO, effective April 13, 2026, and will also join the Board. Dr. Kadia brings extensive experience in scaling life sciences businesses and commercializing innovative technologies.
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Mesa Laboratories, Inc. announced that Gary Owens will step down as President and CEO on April 12, 2026, after leading significant growth and expansion for the company since 2017. Dr. Siddhartha Kadia has been appointed as the new President and CEO, effective April 13, 2026, and will also join the Board. Dr. Kadia brings extensive experience in scaling life sciences businesses and commercializing innovative technologies.
Mesa leadership shift: Gary Owens exits, Siddhartha Kadia takes CEO role
Mesa Laboratories (NASDAQ: MLAB) announced a leadership transition, with Gary Owens stepping down as President and CEO on April 12, 2026. Dr. Siddhartha Kadia will assume the roles of President and CEO and join the Board of Directors effective April 13, 2026. Dr. Kadia brings extensive experience in scaling life sciences businesses, having held prior CEO roles at Calibre Scientific and EAG Laboratories and overseeing a $2 billion business at Life Technologies.
Mesa Labs names Dr. Siddhartha Kadia as new CEO
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced Dr. Siddhartha Kadia will succeed Gary Owens as President and CEO, effective April 13, 2026. Owens, who led Mesa through growth and market expansion since 2017 while maintaining 24 consecutive years of dividend payments, will step down on April 12, 2026. Dr. Kadia brings extensive experience from leadership roles at Calibre Scientific, PhenomeX, EAG Laboratories, and Life Technologies, and will also join Mesa's Board of Directors.
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Mesa Laboratories, Inc. announced that Gary Owens will step down as President and CEO on April 12, 2026. The Board of Directors has appointed Dr. Siddhartha Kadia as the new President and Chief Executive Officer, effective April 13, 2026. Dr. Kadia brings extensive experience in scaling life sciences businesses and will also join the Board.
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Mesa Laboratories, Inc. announced that Gary Owens will step down as President and CEO on April 12, 2026, after leading the company through a period of significant growth. The Board of Directors has appointed Dr. Siddhartha Kadia as the new President and Chief Executive Officer, effective April 13, 2026, recognizing his extensive experience in scaling life sciences businesses. Dr. Kadia expressed his enthusiasm for building on Mesa's foundation and delivering long-term value for stakeholders.
Mesa Laboratories (NASDAQ: MLAB) taps Siddhartha Kadia to succeed CEO Gary Owens
Mesa Laboratories (NASDAQ: MLAB) has announced a leadership transition, with Dr. Siddhartha Kadia appointed to succeed Gary Owens as President and CEO, effective April 13, 2026. Owens, who has served as CEO since 2017, will step down on April 12, 2026, with the company noting his departure is not due to any disagreements. Dr. Kadia's compensation package includes an annual base salary of $850,000, a target annual bonus of at least 100% of his salary, and equity awards (RSUs and PSUs) each valued at $3.0 million, subject to multi-year vesting and performance conditions.
Mesa Labs names Dr. Siddhartha Kadia as new CEO
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced Dr. Siddhartha Kadia as its new President and CEO, effective April 13, 2026, succeeding Gary Owens. Dr. Kadia brings extensive leadership experience from various life sciences companies, including Calibre Scientific and PhenomeX. Owens, who led Mesa Labs since 2017, facilitated company growth and maintained dividend payments for 24 consecutive years.
76,657 Shares in Mesa Laboratories, Inc. $MLAB Acquired by Roubaix Capital LLC
Roubaix Capital LLC recently acquired 76,657 shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) worth approximately $5.14 million, representing about 2.4% of Roubaix's portfolio. This investment gives Roubaix Capital roughly 1.39% ownership of MLAB. The acquisition follows Mesa Laboratories reporting strong Q4 results, beating revenue and EPS expectations, along with a declared quarterly dividend.
Here's Why Conestoga Capital Advisors Sold Mesa Laboratories (MLAB)
Conestoga Capital Advisors sold its position in Mesa Laboratories (MLAB), citing a lack of conviction in the company’s long-term growth prospects. The asset management firm noted that MLAB's operating results were pressured by end-market weakness, particularly in cell and gene therapy and China, and that its acquisition strategy had not delivered anticipated growth. Conestoga concluded that limited organic growth opportunities and a constrained balance sheet limit MLAB’s overall growth potential.
Here’s Why Conestoga Capital Advisors Sold Mesa Laboratories (MLAB)
Conestoga Capital Advisors sold its position in Mesa Laboratories (MLAB) due to a lack of conviction in the company’s long-term growth prospects. The company's operating results have been negatively impacted by end-market weakness and an acquisition strategy that hasn't delivered anticipated growth. Conestoga views MLAB's overall growth potential as limited, citing a constrained balance sheet and few organic growth opportunities.
As worker safety scrutiny intensifies, Mesa Labs reinforces why primary standard calibration is the only line of defense
Mesa Labs is recommitting to advancing its DryCal primary standard calibration technology due to increased regulatory scrutiny and a generational shift in the workforce affecting workplace exposure monitoring. Inaccurate air sampling pump calibration, often relying on less precise secondary standards, poses a significant risk to worker safety. Mesa Labs aims to educate professionals on the importance of primary standards, noted by OSHA's adoption of their Defender series calibrators.
As Worker Safety Scrutiny Intensifies, Mesa Labs Reinforces Why Primary Standard Calibration Is the Only Line of Defense
Mesa Laboratories is emphasizing the critical role of primary standard calibration, specifically its DryCal product line, in ensuring worker safety amidst increasing regulatory scrutiny and a generational knowledge gap in industrial hygiene. The company highlights that unlike secondary standards, their primary standards provide direct, accurate measurements crucial for detecting hazardous exposures, a distinction recognized by OSHA which has standardized its field enforcement on Mesa's Defender series calibrators. Mesa Labs is also partnering with AIHA to educate professionals on flow calibration essentials and the importance of precise instrumentation.
As Worker Safety Scrutiny Intensifies, Mesa Labs Reinforces Why Primary Standard Calibration Is the Only Line of Defense
Mesa Laboratories is emphasizing the critical role of primary standard calibration, particularly through its DryCal product line, amidst increasing regulatory scrutiny on worker safety and a generational knowledge gap in flow calibration. OSHA has standardized its field enforcement operations on Mesa’s Defender series calibrators, highlighting the need for accurate air sampling in hazardous environments. Mesa Labs is also partnering with the AIHA to provide education on calibration essentials for occupational health and safety professionals.
Mesa Laboratories (NasdaqGS:MLAB) Stock Price
Mesa Laboratories, Inc. (MLAB) has a market capitalization of US$515.1 million and its stock price has decreased by 32.94% over the last year. The company reported US$247.5 million in revenue and US$3.7 million in earnings, with moderate growth potential but also a new major risk identified in its financial position. Mesa Laboratories develops and sells life sciences tools and quality control products, operating in various segments including Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions.
Mesa Laboratories, Inc. $MLAB Shares Acquired by Herald Investment Management Ltd
Herald Investment Management Ltd significantly increased its stake in Mesa Laboratories (MLAB) by 300%, now owning 50,000 shares worth $3.34 million. This move is part of broader institutional investment, with various hedge funds also adjusting their positions in the medical instruments supplier. Despite Mesa Laboratories reporting an earnings beat, analysts maintain a "Reduce" consensus rating with a target price of $94.00, while the company also announced a quarterly dividend of $0.16 per share.
Mesa Laboratories, Inc. $MLAB Shares Bought by Diamond Hill Capital Management Inc.
Diamond Hill Capital Management Inc. significantly increased its stake in Mesa Laboratories (MLAB) by 218% in Q3, now owning 2.24% of the company worth $8.27 million. Institutional investors collectively hold approximately 90.6% of the stock. Analyst ratings are mixed, with a MarketBeat consensus of "Reduce" and a target price of $94, while the company recently exceeded Q3 earnings and revenue expectations and declared a quarterly dividend.
Mesa Laboratories (NASDAQ:MLAB) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen upgraded Mesa Laboratories (NASDAQ:MLAB) from a "buy" to a "strong-buy" rating, causing the stock to trade up 2.3% to $93.27. The company recently beat quarterly earnings estimates with an EPS of $3.07 on $65.13 million in revenue, though it carries a high P/E ratio of 145.74. While analyst views are mixed with an average target price of $94, institutional ownership remains high at 90.6%.
Mesa Laboratories (MLAB) Quarterly Profit Return Tests Longstanding Bearish Loss Narratives
Mesa Laboratories (MLAB) recently reported a quarterly profit of US$0.45 EPS on US$60.7 million revenue, contrasting with a US$1.6 million net loss over the trailing twelve months. Despite historical losses, analysts forecast 3.7% annual revenue growth and 16.3% earnings growth, leading to a mixed outlook on profitability. The stock currently trades at a 2x P/S multiple, below its peers and a DCF fair value of US$147.77, suggesting potential undervaluation if the company sustains its recent return to quarterly profits.
Mesa Labs Announces Third Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced its financial results for the third fiscal quarter ended December 31, 2025 (3Q26). The company reported a 3.6% increase in revenues and a 38.0% increase in operating income. Non-GAAP adjusted operating income, excluding unusual items, rose by 15.4% to 26.2% as a percentage of revenues, and Mesa also repaid $8.7 million of debt, reducing its Total Net Leverage Ratio to 2.62.
MESA LABORATORIES INC /CO/ SEC 10-Q Report
Mesa Laboratories Inc. (MLAB) has released its 10-Q report for the period ending December 31, 2025, showing significant financial and operational improvements. The company reported increased revenues and a swing from a net loss to a net income, driven by growth in its Biopharmaceutical Development and Sterilization and Disinfection Control divisions. Despite challenges in the Clinical Genomics division in China, Mesa Labs anticipates continued profitability through strategic initiatives and cost reduction.
